ozanimod (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Multiple Sclerosis

Pending FDA approval for relapsing forms of multiple sclerosis (MS)

Next:

Pharmacology

Mechanism of Action

Oral, sphingosine 1-phosphate (S1P) receptor modulator

Binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5); blocks lymphocyte egress from lymph nodes, reducing the number of lymphocytes in peripheral blood

Mechanism by which siponimod exerts therapeutic effects in MS is unknown, but may involve reduction of lymphocyte migration into the central nervous system

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.